Company news

NextCure, Inc. news in 2025

NextCure, Inc.'s news releases, calls and decks from 2025, newest first.

View company

NextCure to Present at the Piper Sandler 37th Annual Healthcare Conference

November 20, 2025

NextCure Announces Closing of $21.5 Million PIPE Financing in Advance of First Half 2026 Phase 1 POC Data Readouts

November 17, 2025

NextCure Announces $21.5 Million Private Placement of Common Stock Priced at the Market Under Nasdaq Rules

November 12, 2025

NextCure Provides Business Update and Reports Third Quarter 2025 Financial Results

November 5, 2025

NextCure and Simcere Zaiming Announce Expansion of Ongoing Phase 1 Trial of SIM0505 (CDH6 ADC) into the United States

October 16, 2025

NextCure to Present at the H.C. Wainwright 27th Annual Global Investment Conference

September 4, 2025

NextCure Provides Business Update and Reports Second Quarter 2025 Financial Results

August 7, 2025

Preclinical Data Demonstrate Anti-Siglec-15 Treatment Improves Bone Microarchitecture and Reduces Fracture Incidence in Mice with Moderate-to-Severe Osteogenesis Imperfecta

July 24, 2025

NextCure and Simcere Zaiming Announce Strategic Partnership for a Novel Antibody-Drug Conjugate Targeting CDH6

June 16, 2025

NextCure and LigaChemBio to Present Trial in Progress Poster for LNCB74, a B7-H4 Targeted Antibody-Drug Conjugate, as Monotherapy in Participants with Advanced Solid Tumors at ASCO 2025

May 29, 2025

NextCure Provides Business Update and Reports First Quarter 2025 Financial Results

May 1, 2025

NextCure to Present at 24th Annual Needham Virtual Healthcare Conference

April 4, 2025

NextCure Provides Business Update and Reports Full Year 2024 Financial Results

March 6, 2025

NextCure Announces First Patient Dosed in the Phase 1 Study of LNCB74 (B7-H4 ADC) as Therapeutic for Treating Multiple Cancers

January 9, 2025

Decks in 2025